Item Type | Name |
Academic Article
|
Secreted growth factors from estrogen receptor-negative human breast cancer do not support growth of estrogen receptor-positive breast cancer in the nude mouse model.
|
Academic Article
|
Multiple estrogen receptor assays in human breast cancer.
|
Academic Article
|
Measurement of steroid hormone receptors in breast cancer patients on tamoxifen.
|
Academic Article
|
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.
|
Academic Article
|
Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States.
|
Academic Article
|
The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients.
|
Academic Article
|
Time-dependence of hazard ratios for prognostic factors in primary breast cancer.
|
Academic Article
|
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.
|
Academic Article
|
Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
|
Academic Article
|
Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth.
|
Academic Article
|
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
|
Academic Article
|
Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor.
|
Academic Article
|
Statistical analysis of array expression data as applied to the problem of tamoxifen resistance.
|
Academic Article
|
Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance.
|
Academic Article
|
Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation.
|
Academic Article
|
HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
|
Academic Article
|
Selective estrogen receptor modulators: structure, function, and clinical use.
|
Academic Article
|
Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo.
|
Academic Article
|
Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.
|
Academic Article
|
Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.
|
Academic Article
|
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.
|
Academic Article
|
Aromatase inhibitors: future directions.
|
Academic Article
|
Estrogen receptor: current understanding of its activation and modulation.
|
Academic Article
|
Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressor.
|
Academic Article
|
Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies.
|
Academic Article
|
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
|
Academic Article
|
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
|
Academic Article
|
The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth.
|
Academic Article
|
Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth.
|
Academic Article
|
The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer.
|
Academic Article
|
Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer.
|
Academic Article
|
Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.
|
Academic Article
|
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
|
Academic Article
|
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
|
Academic Article
|
Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.
|
Academic Article
|
Estrogen-receptor biology: continuing progress and therapeutic implications.
|
Academic Article
|
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.
|
Academic Article
|
Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
|
Academic Article
|
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).
|
Academic Article
|
Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer.
|
Academic Article
|
Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient.
|
Academic Article
|
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.
|
Academic Article
|
Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
|
Academic Article
|
Breast Cancer: Blocking both driver and escape pathways improves outcomes.
|
Academic Article
|
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
|
Academic Article
|
Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial.
|
Academic Article
|
Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
|
Academic Article
|
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
|
Academic Article
|
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
|
Academic Article
|
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.
|
Academic Article
|
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
|
Academic Article
|
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
|
Academic Article
|
Mechanisms of endocrine resistance in breast cancer.
|
Academic Article
|
Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor.
|
Academic Article
|
Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression.
|
Academic Article
|
Mechanisms of tamoxifen resistance.
|
Academic Article
|
Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo.
|
Academic Article
|
Significance of axillary lymph node metastasis in primary breast cancer.
|
Academic Article
|
HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer.
|
Academic Article
|
High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer.
|
Academic Article
|
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
|
Academic Article
|
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.
|
Academic Article
|
Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters.
|
Academic Article
|
Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer.
|
Academic Article
|
Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
|
Academic Article
|
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.
|
Academic Article
|
Insights into the role of progesterone receptors in breast cancer.
|
Academic Article
|
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
|
Academic Article
|
Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy.
|
Academic Article
|
Molecular profiles of progesterone receptor loss in human breast tumors.
|
Academic Article
|
Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.
|
Academic Article
|
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.
|
Concept
|
Estrogen Receptor Modulators
|
Concept
|
Estrogen Antagonists
|
Concept
|
Estrogen Receptor beta
|
Concept
|
Receptors, Estrogen
|
Concept
|
Estrogens
|
Concept
|
Selective Estrogen Receptor Modulators
|
Concept
|
Estrogen Receptor alpha
|
Academic Article
|
A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative.
|
Academic Article
|
Cancer Res
|
Academic Article
|
AACR
|
Academic Article
|
SABCS
|
Academic Article
|
In vitro model systems for the study of hormone-dependent human breast cancer.
|
Academic Article
|
Current use of steroid hormone receptor assays in the treatment of breast cancer.
|
Academic Article
|
Therapy for cancer of the breast. Current status of steroid hormone receptors.
|
Academic Article
|
The use of stero?d hormone receptors in the treatment of human breast cancer: a review.
|
Academic Article
|
Hormone receptors in primary and advanced breast cancer.
|
Academic Article
|
The value of estrogen and progesterone receptors in the treatment of breast cancer.
|
Academic Article
|
Modern approaches to the treatment of breast cancer.
|
Academic Article
|
Steroid hormone receptors in the management of human breast cancer.
|
Academic Article
|
Correlation of primary breast cancer histopathology and estrogen receptor content.
|
Academic Article
|
Combined chemo-hormonal therapy in breast cancer: a hypothesis.
|
Academic Article
|
Adjuvant therapy for stage II, estrogen receptor negative breast cancer.
|
Academic Article
|
Estrogen receptor, a marker for human breast cancer differentiation and patient prognosis.
|
Academic Article
|
Steroid hormone receptors and carcinoma of the breast.
|
Academic Article
|
Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase.
|
Academic Article
|
Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer.
|
Academic Article
|
Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture.
|
Academic Article
|
Hormone receptors in the management of breast cancer.
|
Academic Article
|
Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.
|
Academic Article
|
Heterogeneity in hormone receptor status in primary and metastatic breast cancer.
|
Academic Article
|
A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study).
|
Academic Article
|
Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status.
|
Academic Article
|
Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status.
|
Academic Article
|
Endocrine therapy testing of human breast cancers in the soft agar clonogenic assay.
|
Academic Article
|
Biological differences among MCF-7 human breast cancer cell lines from different laboratories.
|
Academic Article
|
Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy.
|
Academic Article
|
Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.
|
Academic Article
|
Resistance to endocrine therapy. A panel discussion.
|
Academic Article
|
Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells.
|
Academic Article
|
Blockade of the epidermal growth factor receptor inhibits transforming growth factor alpha-induced but not estrogen-induced growth of hormone-dependent human breast cancer.
|
Academic Article
|
Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens.
|
Academic Article
|
Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.
|
Academic Article
|
Adjuvant therapy in node-negative breast cancer. A panel discussion.
|
Academic Article
|
Effects of c-myc overexpression on the growth characteristics of MCF-7 human breast cancer cells.
|
Academic Article
|
Therapy in premenopausal women with advanced, oestrogen positive or/and progesterone positive breast cancer: surgical oophorectomy versus the LHRH analogue, Zoladex.
|
Academic Article
|
Megestrol acetate in breast cancer--a panel discussion.
|
Academic Article
|
Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status.
|
Academic Article
|
Regulation of breast cancer growth by insulin-like growth factors.
|
Academic Article
|
Growth factors as mediators of estrogen/antiestrogen action in human breast cancer cells.
|
Academic Article
|
Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen.
|
Academic Article
|
Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor.
|
Academic Article
|
Chemotherapy versus observation in high-risk node-negative breast cancer patients.
|
Academic Article
|
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu.
|
Academic Article
|
Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study.
|
Academic Article
|
One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study.
|
Academic Article
|
Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism.
|
Academic Article
|
Recruitment with high physiological doses of estradiol preceding chemotherapy: flow cytometric and therapeutic results in women with locally advanced breast cancers--a Southwest Oncology Group study.
|
Academic Article
|
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
|
Academic Article
|
Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896.
|
Academic Article
|
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.
|
Academic Article
|
Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
|
Academic Article
|
bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study.
|
Academic Article
|
Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors.
|
Academic Article
|
Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
|
Academic Article
|
Cytological evaluation of biological prognostic markers from primary breast carcinomas.
|
Academic Article
|
Oestrogen receptors and breast cancer.
|
Academic Article
|
Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.
|
Academic Article
|
Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study.
|
Academic Article
|
HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
|
Academic Article
|
Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study).
|
Academic Article
|
Steroid hormone receptors in breast cancer management.
|
Academic Article
|
Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer.
|
Academic Article
|
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.
|
Academic Article
|
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer.
|
Academic Article
|
Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.
|
Academic Article
|
ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen.
|
Academic Article
|
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
|
Academic Article
|
Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience.
|
Academic Article
|
Targeting HER2 for the treatment of breast cancer.
|